Circulating miR-1826 in plasma correlates with circulating tumor cells and is a prognostic marker in colorectal cancer

被引:1
作者
Xu, Zhihua [1 ]
Xi, Tianyi [2 ]
Han, Ye [1 ]
Guo, Xiaobo [3 ]
Liu, Fei [4 ]
Jiang, Min [5 ]
Wan, Daiwei [1 ]
Xue, Xiaofeng [1 ]
He, Songbing [1 ]
Ren, Rui [1 ]
Li, Wei [5 ]
Zhi, Qiaoming [1 ]
机构
[1] Soochow Univ, Affiliated Hosp 1, Dept Gen Surg, Suzhou 215006, Peoples R China
[2] Nanjing Med Univ, Affiliated Suzhou Hosp, Suzhou Municipal Hosp, Dept Gen Surg, Suzhou, Peoples R China
[3] Shandong Univ, Shandong Prov Hosp, Dept Gastrointestinal Surg, Jinan, Peoples R China
[4] Soochow Univ, Dept Gastroenterol, Affiliated Hosp 1, Suzhou, Peoples R China
[5] Soochow Univ, Affiliated Hosp 1, Dept Oncol, Suzhou 215006, Peoples R China
基金
中国国家自然科学基金;
关键词
MiR-1826; circulating tumor cells; biomarker; colorectal cancer; CLINICAL-SIGNIFICANCE; BIOMARKERS; MICRORNAS; EXPRESSION; COMPLEMENTARY; RESISTANCE; CARCINOMA; SURVIVAL; CONFERS; GROWTH;
D O I
10.1177/1010428317705333
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Our previous study showed that miR-1826 was a newly identified oncogenic non-coding RNA in colorectal cancer. But the potential relationship between miR-1826 and tumor metastasis has not been fully elucidated. The purpose of this study was to evaluate the clinical significance of circulating miR-1826 and its possible associations with circulating tumor cells in colorectal cancer. Our results first found that serum miR-1826 was significantly upregulated in colorectal cancer patients, compared with that in healthy volunteers (p = 0.003). Similar results were also found in colorectal cancer with distant metastasis (p = 0.001) and advanced colorectal cancer (p < 0.001) patients, respectively. Clinicopathological analysis implied that circulating miR-1826 was positively associated with pT stage (p = 0.026), lymphatic metastasis (p = 0.034), distant metastasis (p = 0.012), and tumor-node-metastasis stage (p = 0.020). Besides, our univariate and multivariate analyses demonstrated that high serum miR-1826 expression could act as a prognostic and independent factor for overall survival of colorectal cancer patients (p < 0.05), which led to a poorer 5-year overall survival rate (p = 0.025). The area under the curve value of circulating miR-1826 was up to 0.848 +/- 0.043, which strongly suggested serum miR-1826 as an effective diagnostic biomarker in colorectal cancer patients (p < 0.001). Our subsequent experiments demonstrated that patients with high level of circulating tumor cells showed a higher level of miR-1826 expression, compared with the circulating tumor cell-negative patients (p = 0.011). Similar results also showed that the amount of circulating tumor cells in high miR-1826 group was significantly higher than that in low miR-1826 group (p = 0.001). Furthermore, the relationship between serum miR-1826 and circulating tumor cells was analyzed using SPSS software and a significant logarithmic relationship was found, which meant that circulating miR-1826 closely correlated with the amount of circulating tumor cells in colorectal cancer patient serum (r = 0.283, p < 0.01). Our findings strongly suggested that serum miR-1826 could serve as an effective and non-invasive biomarker for diagnosis and prognosis of colorectal cancer. Circulating miR-1826 may be an important target in colorectal cancer therapy.
引用
收藏
页数:9
相关论文
共 37 条
[1]   MRP1 expression in CTCs confers resistance to irinotecan-based chemotherapy in metastatic colorectal cancer [J].
Abdallah, Emne Ali ;
Fanelli, Marcello Ferretti ;
Souza e Silva, Virgilio ;
Machado Netto, Marcelo Calil ;
Gasparini Junior, Jose Luiz ;
Araujo, Daniel Vilarim ;
Mendonca Ocea, Luciana Menezes ;
Cavicchioli Buim, Marcilei Eliza ;
Tariki, Milena Shizue ;
Alves, Vanessa da Silva ;
de Andrade, Victor Piana ;
Abbade Dettino, Aldo Lourenco ;
Lopes de Mello, Celso Abdon ;
Domingos Chinen, Ludmilla Thome .
INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (04) :890-898
[2]   Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients [J].
Abdallah, Emne Ali ;
Fanelli, Marcello Ferretti ;
Cavicchioli Buim, Marcilei Eliza ;
Machado Netto, Marcelo Calil ;
Gasparini Junior, Jose Luiz ;
Souza e Silva, Virgilio ;
Abbade Dettino, Aldo Lourenco ;
Mingues, Natalia Breve ;
Romero, Juliana Valim ;
Mendonca Ocea, Luciana Menezes ;
Malagoli Rocha, Bruna Maria ;
Alves, Vanessa Silva ;
Araujo, Daniel Vilarim ;
Domingos Chinen, Ludmilla Thome .
INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (06) :1397-1405
[3]   Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer [J].
Aragon-Ching, Jeanny B. ;
Siegel, Robert S. ;
Frazier, Harold, II ;
Andrawis, Ramez ;
Hendricks, Frederick ;
Phillips, Michael ;
Jarrett, Thomas ;
Guebre-Xabiher, Hiwot ;
Patierno, Steven ;
Simmens, Samuel J. .
CLINICAL GENITOURINARY CANCER, 2015, 13 (05) :E341-E345
[4]   Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer [J].
Basati, Gholam ;
Razavi, Amirnader Emami ;
Pakzad, Iraj ;
Malayeri, Fardin Ali .
TUMOR BIOLOGY, 2016, 37 (02) :1781-1788
[5]   MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer [J].
Cekaite, Lina ;
Eide, Peter W. ;
Lind, Guro E. ;
Skotheim, Rolf I. ;
Lothe, Ragnhild A. .
ONCOTARGET, 2016, 7 (06) :6476-6505
[6]   MicroRNA-223 and microRNA-92a in stool and plasma samples act as complementary biomarkers to increase colorectal cancer detection [J].
Chang, Pi-Yueh ;
Chen, Chia-Chun ;
Chang, Yu-Sun ;
Tsai, Wen-Sy ;
You, Jeng-Fu ;
Lin, Geng-Ping ;
Chen, Ting-Wen ;
Chen, Jinn-Shiun ;
Chan, Err-Cheng .
ONCOTARGET, 2016, 7 (09) :10663-10675
[7]   The use of circulating microRNAs as diagnostic biomarkers in colorectal cancer [J].
Clancy, Cillian ;
Joyce, Myles R. ;
Kerin, Michael J. .
CANCER BIOMARKERS, 2015, 15 (02) :103-113
[8]   Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer [J].
Cohen, S. J. ;
Punt, C. J. A. ;
Iannotti, N. ;
Saidman, B. H. ;
Sabbath, K. D. ;
Gabrail, N. Y. ;
Picus, J. ;
Morse, M. A. ;
Mitchell, E. ;
Miller, M. C. ;
Doyle, G. V. ;
Tissing, H. ;
Terstappen, L. W. M. M. ;
Meropol, N. J. .
ANNALS OF ONCOLOGY, 2009, 20 (07) :1223-1229
[9]   Cytokeratin 20 positive circulating tumor cells are a marker for response after neoadjuvant chemoradiation but not for prognosis in patients with rectal cancer [J].
Hinz, Sebastian ;
Roeder, Christian ;
Tepel, Juergen ;
Hendricks, Alexander ;
Schafmayer, Clemens ;
Becker, Thomas ;
Kalthoff, Holger .
BMC CANCER, 2015, 15
[10]   Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives [J].
Holch, Julian ;
Stintzing, Sebastian ;
Heinemann, Volker .
VISCERAL MEDICINE, 2016, 32 (03) :178-183